Table 2. Baseline patient characteristics.
| Patients screened (N=212) | Patients included (N=17) | |
|---|---|---|
| Age at registration (years): median (range) | 64 (38–86) | 64 (42–77) |
| Sex: n (%) | ||
| Female | 97 (45.8) | 8 (47.1) |
| Tumour stage at first diagnosis: n (%) | ||
| I | 3 (1.6) | 0 (0) |
| II | 16 (8.7) | 2 (11.8) |
| III | 60 (32.6) | 4 (23.5) |
| IV | 47 (25.5) | 7 (41.2) |
| Not evaluable | 58 (31.5) | 4 (23.5) |
| Not available | 28 | — |
| Adenocarcinoma: n (%) | ||
| Yes | 202 (98.1) | 17 (100) |
| No | 4 (1.9) | 0 |
| Not available | 6 | — |
| IHC/FISH: n (%) | ||
| 0 | 83 (40.1) | 0 |
| 1+ | 71 (34.3) | 0 |
| 2+/FISH− | 30 (14.5) | 0 |
| 2+/FISH+ | 1 (0.5) | 1 (5.9) |
| 3+ | 22 (10.6) | 16 (94.1) |
| Not available | 5 | — |
| CA 19–9 (U ml−1), median (range); not available: n=22 | 766 (0–190, 953) | 796 (8–130, 603) |
Abbreviations: CA=carbohydrate antigen; FISH=fluorescence in situ hybridisation; IHC=immunohistochemistry.